Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
327.20
-0.67 (-0.20%)
Mar 31, 2025, 1:27 PM EDT - Market open
Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals had 528 employees as of December 31, 2024. The number of employees increased by 152 or 40.43% compared to the previous year.
Employees
528
Change (1Y)
152
Growth (1Y)
40.43%
Revenue / Employee
$341,161
Profits / Employee
-$882,371
Market Cap
7.22B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
MDGL News
- 20 days ago - Madrigal Appoints Jacqualyn A. Fouse, Ph.D. - GlobeNewsWire
- 4 weeks ago - Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade) - Seeking Alpha
- 4 weeks ago - Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis - Benzinga
- 4 weeks ago - Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook - Seeking Alpha
- 4 weeks ago - Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis - GlobeNewsWire
- 4 weeks ago - Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis - GlobeNewsWire
- 5 weeks ago - Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference - GlobeNewsWire